Arizona Tribune - PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025

The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid at the conference should contact their ISG representative.

About PolyPid Ltd.

PolyPid Ltd. is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional PolyPid information, please visit http://www.polypid.com and follow on Twitter and LinkedIn.

Event: Q1 Investor Summit Virtual Conference
Presentation Time: 10:00 AM ET
Location: https://www.webcaster4.com/Webcast/Page/3082/52088

Conference Overview and Structure

The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.

This quarter's event is focused on MicroCap companies who are undervalued, have a catalyst, and are undervalued.

Registration for Investors

To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.

Sponsors:

• ACCESS Newswire

• PCG Advisory

• QuoteMedia

• AGP

• MZ Group

News Compliments of ACCESS Newswire

For More Information please visit: https://investorsummitgroup.com/
Or contact [email protected]

SOURCE: PolyPid Ltd.

View the original press release on ACCESS Newswire

T.Perez--AT